VLON Vallon Pharmaceuticals, Inc. Stock Quote

VLON [NASD]

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	52.96%	Shs Outstand	9.14M	Perf Week	-44.18%
Market Cap	5.20M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	0.00%	Shs Float	3.21M	Perf Month	-53.33%
Income	-9.30M	PEG	-	EPS next Q	-0.23	Inst Own	6.80%	Short Float	10.01%	Perf Quarter	-89.81%
Sales	-	P/S	-	EPS this Y	-100.90%	Inst Trans	-3.12%	Short Ratio	0.09	Perf Half Y	-88.14%
Book/sh	1.28	P/B	0.44	EPS next Y	16.10%	ROA	-	Target Price	12.00	Perf Year	-85.02%
Cash/sh	0.56	P/C	1.02	EPS next 5Y	-	ROE	-	52W Range	0.49 - 10.36	Perf YTD	-90.48%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-94.50%	Beta	-
Dividend %	-	Quick Ratio	2.30	Sales past 5Y	-	Gross Margin	-	52W Low	16.33%	ATR	0.21
Employees	3	Current Ratio	2.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	27.82	Volatility	27.24% 19.33%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.04	Prev Close	0.57
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	3.70M	Price	0.57
Recom	2.00	SMA20	-52.64%	SMA50	-75.70%	SMA200	-88.62%	Volume	29,748	Change	0.11%

May-13-22 08:30AM	Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering GlobeNewswire -25.39%
May-12-22 08:30AM	Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR GlobeNewswire -8.02%
May-11-22 08:35AM	Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR GlobeNewswire -5.56%
May-09-22 04:05PM	Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire -6.87%
Apr-22-22 08:00AM	Vallon Pharmaceuticals Announces Review of Strategic Alternatives GlobeNewswire +100.88%
Mar-23-22 08:00AM	Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum GlobeNewswire
Mar-21-22 11:02AM	Vallon Pharmaceuticals stock plunges almost 70% after drug candidate misses primary endpoint American City Business Journals -68.95%
07:00AM	Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD GlobeNewswire
Mar-04-22 02:34PM	Lab notes: Myonex acquires German drug business; Vallon receives Covid drug treatment patent American City Business Journals
Feb-28-22 04:05PM	Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors GlobeNewswire -5.98%
08:05AM	Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19 GlobeNewswire
Feb-14-22 04:15PM	Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update GlobeNewswire
Jan-25-22 09:54AM	Even with Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) stock down 13% this week, insiders who bought recently netted around US$20k Simply Wall St.
Jan-20-22 08:35AM	Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference GlobeNewswire -8.81%
Jan-18-22 08:05AM	Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference GlobeNewswire -9.45%
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th ACCESSWIRE
Jan-04-22 08:05AM	Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference GlobeNewswire +12.99%
Dec-23-21 08:05AM	Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR GlobeNewswire
Dec-12-21 04:27AM	12 Penny Stocks Most Popular on Reddit and Robinhood Insider Monkey
Nov-12-21 08:05AM	Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-11-21 08:05AM	Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event GlobeNewswire +6.26%
Nov-10-21 08:35AM	Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference GlobeNewswire -9.62%
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th ACCESSWIRE +11.82%
Nov-01-21 08:35AM	Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting GlobeNewswire
Oct-26-21 03:23PM	We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully Simply Wall St.
Oct-12-21 08:35AM	Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements GlobeNewswire
Sep-14-21 08:05AM	Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board GlobeNewswire -13.94%
Aug-11-21 08:05AM	Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit GlobeNewswire
Aug-10-21 08:05AM	Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-13-21 08:05AM	Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR GlobeNewswire
May-30-21 04:48AM	Insider Buying: The Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Independent Non-Executive Director Just Bought US$72k Worth Of Shares Simply Wall St.
May-19-21 08:15AM	We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate Simply Wall St.
May-13-21 09:15AM	Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
May-11-21 09:05AM	Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer GlobeNewswire
May-07-21 08:05AM	Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit GlobeNewswire +5.15%
Apr-26-21 09:05AM	Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum GlobeNewswire
Apr-13-21 08:05AM	Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval GlobeNewswire +15.32%
Mar-29-21 08:05AM	Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire +7.03%
Mar-03-21 08:35AM	Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Feb-23-21 09:05AM	Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors GlobeNewswire
Feb-12-21 03:30PM	Vallon Pharmaceuticals Announces Closing of Initial Public Offering GlobeNewswire
Feb-09-21 10:24PM	Vallon Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Leanne M.	Chief Financial Officer	Jun 04	Buy	4.08	1,508	6,153	6,250	Jun 04 04:06 PM
Kelly Leanne M.	Chief Financial Officer	Jun 03	Buy	4.05	1,085	4,394	4,742	Jun 04 04:06 PM
Kelly Leanne M.	Chief Financial Officer	Jun 02	Buy	4.00	3,657	14,628	3,657	Jun 04 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience